Literature DB >> 12529276

Reversibility of chronic cyclosporine nephropathy in rats after withdrawal of cyclosporine.

Can Li1, Chul Woo Yang, Wan Young Kim, Ju Young Jung, Jung Ho Cha, Yong Soo Kim, Jin Kim, William M Bennett, Byung Kee Bang.   

Abstract

Renal interstitial inflammation is an important factor in the pathogenesis of chronic cyclosporin A (CsA) nephropathy. We studied the expression of the chemoattractant osteopontin (OPN) and the relationship between OPN expression and tubulointerstitial injury in a rat model of chronic CsA nephropathy. Chronic CsA nephropathy was induced in Sprague-Dawley rats by administering CsA (15 mg/kg sc) for 5 wk and then withdrawing it for 5 or 10 wk. Renal function, histopathology (arteriolopathy, ED-1-positive cells, and tubulointerstitial fibrosis), renin-angiotensin system (RAS) activity, and OPN expression were observed during the follow-up period. Renal function deteriorated in CsA-treated rats, with the development of typical histopathology and activation of RAS. After CsA withdrawal, these parameters were significantly reversed (all P < 0.05). The upregulation of OPN mRNA and protein expression seen in CsA-treated rat kidneys was decreased 5 wk after CsA withdrawal and was further decreased after 10 wk. Of note, OPN mRNA expression correlated with the number of infiltrating macrophage (r = 0.651, P < 0.01) and tubulointerstitial fibrosis (r = 0.729, P < 0.01). These findings suggest that OPN expression and macrophage infiltration decrease after long-term CsA withdrawal in rats with established chronic CsA nephropathy, and this is closely associated with recovery from renal injury.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12529276     DOI: 10.1152/ajprenal.00277.2002

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  8 in total

1.  High-sensitivity C-reactive protein (hs-CRP) level in children with nephrotic syndrome.

Authors:  Anna Wasilewska; Walentyna Zoch-Zwierz; Jolanta Tobolczyk; Edyta Tenderenda
Journal:  Pediatr Nephrol       Date:  2006-11-18       Impact factor: 3.714

Review 2.  The pathogenesis and treatment of chronic allograft nephropathy.

Authors:  Can Li; Chul Woo Yang
Journal:  Nat Rev Nephrol       Date:  2009-07-28       Impact factor: 28.314

3.  Calcineurin-inhibition Results in Upregulation of Local Renin and Subsequent Vascular Endothelial Growth Factor Production in Renal Collecting Ducts.

Authors:  Ágnes Prókai; Rózsa Csohány; Erna Sziksz; Domonkos Pap; Leonóra Balicza-Himer; Szilvia Boros; Balázs Magda; Ádám Vannay; Katalin Kis-Petik; Andrea Fekete; János Peti-Peterdi; Attila J Szabó
Journal:  Transplantation       Date:  2016-02       Impact factor: 4.939

4.  The role of MAPK in drug-induced kidney injury.

Authors:  Hilary Cassidy; Robert Radford; Jennifer Slyne; Sein O'Connell; Craig Slattery; Michael P Ryan; Tara McMorrow
Journal:  J Signal Transduct       Date:  2012-03-12

5.  Incomplete Restoration of Angiotensin II-Induced Renal Extracellular Matrix Deposition and Inflammation Despite Complete Functional Recovery in Rats.

Authors:  Anne-Roos S Frenay; Saleh Yazdani; Miriam Boersema; Anne Marijn van der Graaf; Femke Waanders; Jacob van den Born; Gerjan J Navis; Harry van Goor
Journal:  PLoS One       Date:  2015-06-10       Impact factor: 3.240

6.  Hypoxia Activates Src and Promotes Endocytosis Which Decreases MMP-2 Activity and Aggravates Renal Interstitial Fibrosis.

Authors:  Zhengyuan Cheng; Lei Liu; Zhi Wang; Yingying Cai; Qing Xu; Pingsheng Chen
Journal:  Int J Mol Sci       Date:  2018-02-15       Impact factor: 5.923

Review 7.  Role of Klotho in Chronic Calcineurin Inhibitor Nephropathy.

Authors:  Kang Luo; Sun Woo Lim; Yi Quan; Sheng Cui; Yoo Jin Shin; Eun Jeong Ko; Byung Ha Chung; Chul Woo Yang
Journal:  Oxid Med Cell Longev       Date:  2019-10-17       Impact factor: 6.543

Review 8.  Established and newly proposed mechanisms of chronic cyclosporine nephropathy.

Authors:  Hye Eun Yoon; Chul Woo Yang
Journal:  Korean J Intern Med       Date:  2009-06-08       Impact factor: 2.884

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.